Xinyu Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinyu Huang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Xu Zhang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China
3 shared publications - Daoming Bai
Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China
2 shared publications Mengyuan Liu
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
2 shared publications- Rui Yang
Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China
2 shared publications - Zhiqiang Zhang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
2 shared publications - Chunhong Yu
Department of Hepatobiliary Medicine Fuzong Clinical Medical College of Fujian Medical University Fuzhou China
1 shared publication
Latest Publications
- 13 April 2026
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1558 (1) , e70258
The Nasal Microbiome in Inflammation and Disease: Bridging Mechanisms to Therapeutics
The nasal microbiome, an integral component of the upper respiratory tract's microecological system, plays a pivotal role in inflammatory diseases such as allergic rhinitis and chronic sinusitis, which affect a substantial population and markedly reduce quality of life. A healthy nasal flora and its metabolites are crucial for maintaining immune homeostasis and mucosal barrier integrity. This review comprehensively discusses the pathological mechanisms, immune interactions, and clinical intervention strategies involving the nasal microbiota in nasal inflammation. It has been shown that dysbiosis of the nasal flora disrupts immune function and compromises the epithelial barrier, thereby initiating and exacerbating a vicious cycle of inflammation. Furthermore, the formation of bacterial biofilms and the emergence of drug resistance contribute to persistent and recurrent symptoms. Regarding treatment, while antibiotics may offer short‐term efficacy, they risk aggravating the microbial imbalance. In contrast, therapies including probiotics, novel immunomodulators, and traditional Chinese medicine demonstrate significant therapeutic potential by restoring microbial balance and modulating immune responses. This review synthesizes current research to provide new perspectives for understanding host–microbiome interactions and to guide future clinical treatments and drug development.
- 13 April 2026
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1558 (1) , e70258
The Nasal Microbiome in Inflammation and Disease: Bridging Mechanisms to Therapeutics
The nasal microbiome, an integral component of the upper respiratory tract's microecological system, plays a pivotal role in inflammatory diseases such as allergic rhinitis and chronic sinusitis, which affect a substantial population and markedly reduce quality of life. A healthy nasal flora and its metabolites are crucial for maintaining immune homeostasis and mucosal barrier integrity. This review comprehensively discusses the pathological mechanisms, immune interactions, and clinical intervention strategies involving the nasal microbiota in nasal inflammation. It has been shown that dysbiosis of the nasal flora disrupts immune function and compromises the epithelial barrier, thereby initiating and exacerbating a vicious cycle of inflammation. Furthermore, the formation of bacterial biofilms and the emergence of drug resistance contribute to persistent and recurrent symptoms. Regarding treatment, while antibiotics may offer short‐term efficacy, they risk aggravating the microbial imbalance. In contrast, therapies including probiotics, novel immunomodulators, and traditional Chinese medicine demonstrate significant therapeutic potential by restoring microbial balance and modulating immune responses. This review synthesizes current research to provide new perspectives for understanding host–microbiome interactions and to guide future clinical treatments and drug development.
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation
- Open Access
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Open AccessBacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.